At the end of 2014, there were an estimated 230,470 people living in Australia with chronic hepatitis C infection, of whom 44,730 had severe fibrosis or hepatitis C related cirrhosis.1
An estimated 22,470 individuals initiated DAA treatment during March to June 2016.2
For details on hepatitis C treatment uptake in Australia since the PBS listing of new direct acting antivirals (DAAs) from 1 March 2016, access the Viral Hepatitis Clinical Research Program newsletters titled Monitoring hepatitis C treatment uptake in Australia.
To be eligible for a GP Management Plan (GPMP), the patient in Australia must have a chronic or terminal medical condition. To be eligible for Team Care Arrangements (TCAs), the patient must have a chronic or terminal medical condition that requires ongoing treatment from a multidisciplinary team.
ASHM has developed the GPMP and TCAs for HCV Infection to provide GPs with best practice guidelines in the management of HCV. While this GPMP specifically relates to management of HCV, patients’ other health problems and needs are also addressed. Recommended monitoring and review guidelines are included.
Effective direct acting antiviral (DAA) treatment for hepatitis C is available. In the majority of cases, chronic hepatitis C can now be cured. All people living with HCV infection should be considered for treatment.
The HCV genotype must be documented in the patient’s history to meet PBS criteria for the new HCV medicines, therefore this must be determined prior to treatment initiation.
This general statement provides the prescriber and patient eligibility for subsidisation under the PBS for hepatitis C treating agents
The hepatitis C genotype determines the treatment regimens:
Length of treatment (usually 12 to 24 weeks)
HCV treatments are evolving rapidly with the introduction of direct-acting antiviral (DAA) drugs. These new treatments offer significant clinical benefit with SVR rates greater than 90%, low toxicity and shortened treatment duration.
Prepared by an expert panel, this document provides guidance on epidemiology, models of care, diagnosis, pre-treatment assessment, monitoring and treatment. It is available in various formats:
Developed by GESA-Australian Liver Association, this template can be used by medical practitioners, including general practitioners, to consult with a gastroenterologist, hepatologist, or infectious disease physician experienced in the treatment of chronic hepatitis C infection, in order to prescribe new treatments under the PBS.
This primary care consultation request form is to get authorisation to treat in Victoria. It has some significant differences to above GESA/ALA form, including:
ASHM is working to increase the capacity and confidence of primary care practitioners to diagnose, manage and treat people living with hepatitis C
ASHM receives funding from the Commonwealth Department of Health and Ageing to convene the National HCV Training Standards Committee which develops and endorses national curriculum and training materials and liaises with relevant state and territory jurisdictions for their implementation.